Journal of pain and symptom management · 2025
Pharmacist-led Opioid Deprescribing Pilot Clinic within Outpatient Palliative Care.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lowry Maria Felton, Lee Sydney, Hoke Makayla F, Leung Emily R, Roup Hailey, Linge Hope E, King Linda, Schenker Yael
Аннотация
BACKGROUND: Patients with cancer receiving opioid therapy often follow with specialty palliative care after achieving remission. Strategies to reduce risks associated with ongoing opioid therapy in survivorship are needed.
MEASURES: Feasibility, safety, and impact.
INTERVENTION: A pharmacist-led opioid deprescribing program, embedded within a specialty palliative care clinic, was designed for patients on long-term opioid therapy who have reached cancer remission.
OUTCOMES: In the nine-month pilot phase, 80% of referred patients established care with the pharmacist. One hundred seventeen pharmacist visits occurred: 20 in person, 52 telemedicine, and 45 telephone. The pharmacist spent an average of 72 minutes for initial and 45 minutes for follow-up visits. Oral morphine equivalents (OMEs) were reduced for 75% of referred patients, with an average of 22% reduction. No patients were hospitalized for uncontrolled pain or withdrawal.
CONCLUSION/LESSONS LEARNED: Opioid deprescribing clinic was time-intensive and patients required close monitoring for implementation of patient-specific opioid deprescribing plans.
MEASURES: Feasibility, safety, and impact.
INTERVENTION: A pharmacist-led opioid deprescribing program, embedded within a specialty palliative care clinic, was designed for patients on long-term opioid therapy who have reached cancer remission.
OUTCOMES: In the nine-month pilot phase, 80% of referred patients established care with the pharmacist. One hundred seventeen pharmacist visits occurred: 20 in person, 52 telemedicine, and 45 telephone. The pharmacist spent an average of 72 minutes for initial and 45 minutes for follow-up visits. Oral morphine equivalents (OMEs) were reduced for 75% of referred patients, with an average of 22% reduction. No patients were hospitalized for uncontrolled pain or withdrawal.
CONCLUSION/LESSONS LEARNED: Opioid deprescribing clinic was time-intensive and patients required close monitoring for implementation of patient-specific opioid deprescribing plans.